

Smart Pills - Company Evaluation Report, 2024

<https://marketpublishers.com/r/S82EB468E3C2EN.html>

Date: August 2025

Pages: 104

Price: US\$ 2,650.00 (Single User License)

ID: S82EB468E3C2EN

Abstracts

The Smart Pills Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Smart Pills. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 102 companies, of which the Top 14 Smart Pills Companies were categorized and recognized as quadrant leaders.

Smart pills, also known as ingestible sensors or digital pills, are revolutionary medical devices designed in the form of a swallowable capsule. Once ingested, these high-tech pills travel through the gastrointestinal (GI) tract to perform diagnostic functions or monitor treatment adherence. Common applications include capsule endoscopy, where a tiny camera captures images of the digestive system, and medication monitoring, where an embedded sensor signals when a pill has been taken. The data is transmitted wirelessly from inside the body to an external receiver, providing clinicians with unprecedented, real-time insights.

The market for smart pills is primarily driven by the demand for less invasive diagnostic tools. Capsule endoscopy provides a patient-friendly and effective method for examining the small intestine, an area difficult to reach with traditional scopes. Another major driver is the pressing need to solve the multi-billion-dollar problem of medication non-adherence, especially for patients with chronic conditions. By providing objective confirmation that medication has been taken, smart pills can significantly improve disease management and clinical trial data accuracy. Continuous technological advancements are also making these devices more capable and accessible.

Despite their potential, smart pills face significant challenges. The security and privacy of the sensitive health data they collect and transmit are paramount concerns that must be rigorously addressed. The high cost of the pills and their associated monitoring

systems can be a major barrier to widespread clinical use and reimbursement from insurance providers. The regulatory approval pathway for such novel devices is complex and lengthy. Technical hurdles, such as ensuring reliable data transmission through body tissue and extending the device's battery life, also remain areas of active development.

The 360 Quadrant maps the Smart Pills companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Smart Pills quadrant. The top criteria for product footprint evaluation included Target Area (Small Intestine, Large Intestine, Esophagus, Stomach), Application (Capsule Endoscopy, Patient Monitoring, Targeted Drug Delivery), Disease Indication (Crohn's Disease, Occult Gastrointestinal Bleeding, Small Bowel Tumors, Celiac Disease, Other Disease Indications), End User (Hospitals, Diagnostic Centers, Outpatient Settings, Other End Users)

Key Players:

Major vendors in the Smart Pills market are Medtronic (US), Olympus Corporation (Japan), and CapsoVision, Inc. (US), IntroMedic (South Korea and Shangxian Minimal Invasive Inc. (China), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (China), and AnX Robotics (US), etectRx (US), Check-Cap (Israel), and BodyCap (France).

The key strategies major vendors implement in the Smart Pills market are partnerships, collaborations, product launches, and product enhancements.

Here are the summaries for Medtronic, Olympus Corporation, and CapsoVision, Inc.

Medtronic

Medtronic plc is a global titan in healthcare technology, with a dominant market position across its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios. The company is a leader in everything from pacemakers and insulin pumps to advanced surgical instruments. Strategically, Medtronic is focused on integrating AI, data analytics, and robotics—spearheaded by its Hugo™ surgical robot—into its offerings. Through active portfolio management and innovation in less-invasive technologies, the company aims to transform chronic disease management and surgical care worldwide, including in key growth markets like India.

Olympus Corporation

Olympus Corporation is the world's dominant leader in medical endoscopy, leveraging its legendary optical and digital expertise. The Japanese company provides a comprehensive range of endoscopes and therapeutic devices crucial for minimally invasive diagnosis and treatment in gastroenterology and other specialties. Strategically, Olympus has focused on becoming a pure-play medical technology company, divesting non-core assets. It is now heavily invested in integrating AI into its systems to enhance diagnostic accuracy and expanding its portfolio of therapeutic tools, solidifying its leadership in GI and beyond.

CapsoVision, Inc.

CapsoVision, Inc. is an innovative medical device company specializing in gastrointestinal diagnostics through capsule endoscopy. Its flagship product, the CapsoCam Plus®, sets itself apart with a unique 360-degree panoramic lateral camera, designed to provide a more comprehensive view of the small bowel. The company's strategy is to challenge established market players by leveraging this technological advantage and a simplified, data-recorder-free system for enhanced patient convenience. By focusing on improving diagnostic yield, CapsoVision aims to capture a growing share of the non-invasive GI imaging market.

Contents

1 INTRODUCTION

1.1 MARKET DEFINITION

1.2 STAKEHOLDERS

2 EXECUTIVE SUMMARY

3 MARKET OVERVIEW

3.1 INTRODUCTION

3.2 MARKET DYNAMICS

3.2.1 DRIVERS

3.2.1.1 Rising demand for non-invasive diagnostic monitoring devices

3.2.1.2 Technological advancements in capsule endoscopy

3.2.1.3 Increasing incidence of colon cancer

3.2.2 RESTRAINTS

3.2.2.1 High R&D costs for technological developments and advancements

3.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills

3.2.3 OPPORTUNITIES

3.2.3.1 Innovations in sensor technologies and wireless communication

3.2.3.2 Rising need for rapid drug delivery and development

3.2.4 CHALLENGES

3.2.4.1 Increased patient privacy and data security concerns

3.2.4.2 Shortage of skilled healthcare professionals

3.3 INDUSTRY TRENDS

3.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES

3.3.2 INTEGRATION WITH AI AND ML

3.3.3 INTEGRATION WITH WEARABLE DEVICES

3.4 TECHNOLOGY ANALYSIS

3.4.1 KEY TECHNOLOGIES

3.4.1.1 Wireless communication systems

3.4.1.2 Sensor technologies

3.4.1.3 Self-powered ingestible smart pills

3.4.1.4 Adaptive frame rate technologies

3.4.1.5 iMAG

3.4.1.6 AI and ML

3.4.2 COMPLEMENTARY TECHNOLOGIES

- 3.4.2.1 Robotic technologies
- 3.4.2.2 Data analytics
- 3.4.3 ADJACENT TECHNOLOGIES
 - 3.4.3.1 IoT
 - 3.4.3.2 Cloud computing
- 3.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
- 3.6 PIPELINE ANALYSIS
- 3.7 PORTER'S FIVE FORCES ANALYSIS
 - 3.7.1 INTENSITY OF COMPETITIVE RIVALRY
 - 3.7.2 THREAT OF NEW ENTRANTS
 - 3.7.3 THREAT OF SUBSTITUTES
 - 3.7.4 BARGAINING POWER OF SUPPLIERS
 - 3.7.5 BARGAINING POWER OF BUYERS
- 3.8 ECOSYSTEM ANALYSIS
- 3.9 VALUE CHAIN ANALYSIS
- 3.10 PATENT ANALYSIS
 - 3.10.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
 - 3.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
 - 3.10.3 LIST OF KEY PATENTS
- 3.11 KEY CONFERENCES & EVENTS, 2025–2026
- 3.12 IMPACT OF AI/GEN AI ON SMART PILLS MARKET
 - 3.12.1 KEY USE CASES
 - 3.12.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION
 - 3.12.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding
 - 3.12.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors
 - 3.12.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
 - 3.12.3.1 AI in endoscopy
 - 3.12.3.2 Wearable devices
 - 3.12.3.3 Digital healthcare
 - 3.12.3.4 Home healthcare
 - 3.12.4 USER READINESS & IMPACT ASSESSMENT
 - 3.12.4.1 User readiness
 - 3.12.4.1.1 User A: Hospitals
 - 3.12.4.1.2 User B: Diagnostic centers
 - 3.12.4.2 Impact assessment
 - 3.12.4.2.1 User A: Hospitals

- 3.12.4.2.1.1 Implementation
- 3.12.4.2.1.2 Impact
- 3.12.4.2.2 User B: Diagnostic centers
 - 3.12.4.2.2.1 Implementation
 - 3.12.4.2.2.2 Impact

4 COMPETITIVE LANDSCAPE

4.1 INTRODUCTION

4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

4.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SMART PILLS MARKET

4.3 REVENUE ANALYSIS, 2019–2023

4.4 MARKET SHARE ANALYSIS, 2023

4.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

4.5.1 STARS

4.5.2 EMERGING LEADERS

4.5.3 PERVASIVE PLAYERS

4.5.4 PARTICIPANTS

4.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

4.5.5.1 Company footprint

4.5.5.2 Region footprint

4.5.5.3 Application footprint

4.5.5.4 Target area footprint

4.5.5.5 Disease indication footprint

4.5.5.6 End-user footprint

4.5.5.7 Region footprint

4.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023

4.6.1 PROGRESSIVE COMPANIES

4.6.2 RESPONSIVE COMPANIES

4.6.3 DYNAMIC COMPANIES

4.6.4 STARTING BLOCKS

4.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023

4.6.5.1 Detailed list of key startups/SME players

4.6.5.2 Competitive benchmarking of key startups/SME players

4.7 COMPANY VALUATION & FINANCIAL METRICS

4.7.1 FINANCIAL METRICS

4.7.2 COMPANY VALUATION

4.8 BRAND/PRODUCT COMPARISON

4.9 COMPETITIVE SCENARIO

4.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS

4.9.2 DEALS

4.9.3 OTHER DEVELOPMENTS

5 COMPANY PROFILES

5.1 KEY PLAYERS

5.1.1 MEDTRONIC

5.1.1.1 Business overview

5.1.1.2 Products/Services/Solutions offered

5.1.1.3 Recent developments

5.1.1.3.1 Product approvals & enhancements

5.1.1.3.2 Deals

5.1.1.4 MnM view

5.1.1.4.1 Right to win

5.1.1.4.2 Strategic choices

5.1.1.4.3 Weaknesses & competitive threats

5.1.2 OLYMPUS CORPORATION

5.1.2.1 Business overview

5.1.2.2 Products/Services/Solutions offered

5.1.2.3 Recent developments

5.1.2.3.1 Other developments

5.1.2.4 MnM view

5.1.2.4.1 Right to win

5.1.2.4.2 Strategic choices

5.1.2.4.3 Weaknesses & competitive threats

5.1.3 CAPSOVISION, INC.

5.1.3.1 Business overview

5.1.3.2 Products/Services/Solutions offered

5.1.3.3 Recent developments

5.1.3.3.1 Product approvals & enhancements

5.1.3.4 MnM view

5.1.3.4.1 Right to win

5.1.3.4.2 Strategic choices

5.1.3.4.3 Weaknesses & competitive threats

5.1.4 INTROMEDIC

5.1.4.1 Business overview

5.1.4.2 Products/Services/Solutions offered

- 5.1.4.3 MnM view
 - 5.1.4.3.1 Right to win
 - 5.1.4.3.2 Strategic choices
 - 5.1.4.3.3 Weaknesses & competitive threats
- 5.1.5 JINSHAN SCIENCE & TECHNOLOGY
 - 5.1.5.1 Business overview
 - 5.1.5.2 Products/Services/Solutions offered
 - 5.1.5.3 MnM view
 - 5.1.5.3.1 Right to win
 - 5.1.5.3.2 Strategic choices
 - 5.1.5.3.3 Weaknesses & competitive threats
- 5.1.6 ANX ROBOTICS
 - 5.1.6.1 Business overview
 - 5.1.6.2 Products/Services/Solutions offered
 - 5.1.6.3 Recent developments
 - 5.1.6.3.1 Product launches, approvals, and enhancements
- 5.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
 - 5.1.7.1 Business overview
 - 5.1.7.2 Products/Services/Solutions offered
- 5.1.8 ETECTRX
 - 5.1.8.1 Business overview
 - 5.1.8.2 Products/Services/Solutions offered
 - 5.1.8.3 Recent developments
 - 5.1.8.3.1 Product enhancements
 - 5.1.8.3.2 Deals
- 5.1.9 BODYCAP
 - 5.1.9.1 Business overview
 - 5.1.9.2 Products/Services/Solutions offered
 - 5.1.9.3 Recent developments
 - 5.1.9.3.1 Product launches
 - 5.1.9.3.2 Deals
- 5.1.10 CHECK-CAP
 - 5.1.10.1 Business overview
 - 5.1.10.2 Products/Services/Solutions offered
 - 5.1.10.3 Recent developments
 - 5.1.10.3.1 Product approvals
 - 5.1.10.3.2 Expansions
- 5.1.11 SHANGXIAN MINIMAL INVASIVE INC.
 - 5.1.11.1 Business overview

5.1.11.2 Products/Services/Solutions offered

5.2 OTHER PLAYERS

5.2.1 VELOCE CORPORATION

5.2.2 BIOCAM

5.2.3 ENDIATX

5.2.4 RF CO., LTD.

5.2.5 CELERO SYSTEMS

5.2.6 BIORA THERAPEUTICS, INC.

5.2.7 INNURVATION

5.2.8 RANI THERAPEUTICS

5.2.9 MOTILIS MEDICA SA

6 APPENDIX

6.1 RESEARCH METHODOLOGY

6.1.1 RESEARCH DATA

6.1.1.1 Secondary data

6.1.1.2 Primary data

6.1.2 STUDY ASSUMPTIONS

6.1.3 RISK ANALYSIS

6.1.4 RESEARCH LIMITATIONS

6.2 COMPANY EVALUATION MATRIX: METHODOLOGY

6.3 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 SMART PILLS MARKET: IMPACT ANALYSIS

TABLE 2 SENSOR AND BATTERY TYPES FOR CAPSULE ENDOSCOPY PRODUCTS

TABLE 3 SENSORS USED FOR VITAL SIGN MONITORING PRODUCTS

TABLE 4 SMART PILLS MARKET: DRUGS UNDER PIPELINE

TABLE 5 SMART PILLS MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 6 SMART PILLS MARKET: LIST OF KEY PATENTS, JANUARY 2020–DECEMBER 2024

TABLE 7 SMART PILLS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026

TABLE 8 CASE STUDY 1: CAPSOCAM SV-1 VERSUS PILLCAM SB3 TO DETECT OBSCURE GASTROINTESTINAL BLEEDING

TABLE 9 CASE STUDY 2: AARDEX GROUP PARTNERED WITH ETECTRX, INC. TO TRACK MEDICATION-TAKING BEHAVIORS

TABLE 10 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SMART PILLS MARKET, JANUARY 2021–JANUARY 2025

TABLE 11 SMART PILLS MARKET: DEGREE OF COMPETITION

TABLE 12 SMART PILLS MARKET: REGION FOOTPRINT

TABLE 13 SMART PILLS MARKET: APPLICATION FOOTPRINT

TABLE 14 SMART PILLS MARKET: TARGET AREA FOOTPRINT

TABLE 15 SMART PILLS MARKET: DISEASE INDICATION FOOTPRINT

TABLE 16 SMART PILLS MARKET: END-USER FOOTPRINT

TABLE 17 SMART PILLS MARKET: REGION FOOTPRINT

TABLE 18 SMART PILLS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS

TABLE 19 SMART PILLS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS

TABLE 20 SMART PILLS MARKET: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025

TABLE 21 SMART PILLS MARKET: DEALS, JANUARY 2021–JANUARY 2025

TABLE 22 SMART PILLS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 23 MEDTRONIC: COMPANY OVERVIEW

TABLE 24 MEDTRONIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 25 MEDTRONIC: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025

TABLE 26 MEDTRONIC: DEALS, JANUARY 2021–JANUARY 2025

TABLE 27 OLYMPUS CORPORATION: COMPANY OVERVIEW

TABLE 28 OLYMPUS CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 29 OLYMPUS CORPORATION: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025

TABLE 30 CAPSOVISION, INC.: COMPANY OVERVIEW

TABLE 31 CAPSOVISION, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 32 CAPSOVISION, INC.: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025

TABLE 33 INTROMEDIC: COMPANY OVERVIEW

TABLE 34 INTROMEDIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 35 JINSHAN SCIENCE & TECHNOLOGY: COMPANY OVERVIEW

TABLE 36 JINSHAN SCIENCE & TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 37 ANX ROBOTICS: COMPANY OVERVIEW

TABLE 38 ANX ROBOTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 39 ANX ROBOTICS: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025

TABLE 40 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW

TABLE 41 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS/SERVICES/ SOLUTIONS OFFERED

TABLE 42 ETECTRX: COMPANY OVERVIEW

TABLE 43 ETECTRX: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 44 ETECTRX: PRODUCT ENHANCEMENTS, JANUARY 2021–JANUARY 2025

TABLE 45 ETECTRX: DEALS, JANUARY 2021–JANUARY 2025

TABLE 46 BODYCAP: COMPANY OVERVIEW

TABLE 47 BODYCAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 48 BODYCAP: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025

TABLE 49 BODYCAP: DEALS, JANUARY 2021–JANUARY 2025

TABLE 50 CHECK-CAP: COMPANY OVERVIEW

TABLE 51 CHECK-CAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 52 CHECK-CAP: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025

TABLE 53 CHECK-CAP: EXPANSIONS, JANUARY 2021–JANUARY 2025

TABLE 54 SHANGXIAN MINIMAL INVASIVE INC.: COMPANY OVERVIEW

TABLE 55 SHANGXIAN MINIMAL INVASIVE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED

TABLE 56 VELOCE CORPORATION: COMPANY OVERVIEW
TABLE 57 BIOCAM: COMPANY OVERVIEW
TABLE 58 ENDIATX: COMPANY OVERVIEW
TABLE 59 RF CO., LTD.: COMPANY OVERVIEW
TABLE 60 CELERO SYSTEMS: COMPANY OVERVIEW
TABLE 61 BIORA THERAPEUTICS, INC.: COMPANY OVERVIEW
TABLE 62 INNURVATION: COMPANY OVERVIEW
TABLE 63 RANI THERAPEUTICS: COMPANY OVERVIEW
TABLE 64 MOTILIS MEDICA SA: COMPANY OVERVIEW
TABLE 65 SMART PILLS MARKET: STUDY ASSUMPTIONS
TABLE 66 SMART PILLS MARKET: RISK ANALYSIS

List Of Figures

LIST OF FIGURES

FIGURE 1 SMART PILLS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)

FIGURE 2 SMART PILLS MARKET, BY TARGET AREA, 2024 VS. 2030 (USD MILLION)

FIGURE 3 SMART PILLS MARKET, BY DISEASE INDICATION, 2024 VS. 2030 (USD MILLION)

FIGURE 4 SMART PILLS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)

FIGURE 5 REGIONAL SNAPSHOT OF SMART PILLS MARKET

FIGURE 6 SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 7 HEALTHCARE SECURITY BREACHES OF 500 + RECORDS, 2009–2024

FIGURE 8 SMART PILLS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

FIGURE 9 SMART PILLS MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 10 SMART PILLS MARKET: ECOSYSTEM ANALYSIS

FIGURE 11 SMART PILLS MARKET: VALUE CHAIN ANALYSIS

FIGURE 12 SMART PILLS MARKET: GLOBAL PATENT PUBLICATION TRENDS (2015–2024)

FIGURE 13 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILL PATENTS (JANUARY 2014–DECEMBER 2024)

FIGURE 14 TOP APPLICANTS FOR SMART PILL PATENTS (COUNTRY/REGION) (JANUARY 2014–DECEMBER 2024)

FIGURE 15 MARKET POTENTIAL OF AI/GEN AI ON SMART PILLS ACROSS INDUSTRIES

FIGURE 16 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS

FIGURE 17 REVENUE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET, 2019–2023 (USD MILLION)

FIGURE 18 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET (2023)

FIGURE 19 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023

FIGURE 20 SMART PILLS MARKET: COMPANY FOOTPRINT

FIGURE 21 SMART PILLS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023

FIGURE 22 EV/EBITDA OF KEY VENDORS

FIGURE 23 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 24 SMART PILLS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 25 MEDTRONIC: COMPANY SNAPSHOT

FIGURE 26 OLYMPUS CORPORATION: COMPANY SNAPSHOT

FIGURE 27 SMART PILLS MARKET: RESEARCH DESIGN

FIGURE 28 SMART PILLS MARKET: KEY DATA FROM SECONDARY SOURCES

FIGURE 29 SMART PILLS MARKET: KEY DATA FROM PRIMARY SOURCES

I would like to order

Product name: Smart Pills - Company Evaluation Report, 2024

Product link: <https://marketpublishers.com/r/S82EB468E3C2EN.html>

Price: US\$ 2,650.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S82EB468E3C2EN.html>